| Sep 26 |
Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort
|
| Sep 10 |
enGene Holdings GAAP EPS of -$0.32 beats by $0.07
|
| Sep 10 |
enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update
|
| Aug 28 |
enGene to Participate in Upcoming Investor Conferences
|
| Jul 24 |
enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
|
| Jul 24 |
enGene Announces Appointment of Ron Cooper as Chief Executive Officer
|
| Jul 18 |
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
|
| Jun 14 |
enGene Holdings GAAP EPS of -$0.38
|
| Jun 14 |
enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update
|
| May 29 |
enGene to Present at the Jefferies Global Healthcare Conference
|
